Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.94
-0.10 (-1.42%)
At close: Mar 24, 2026, 4:00 PM EDT
6.99
+0.05 (0.72%)
After-hours: Mar 24, 2026, 6:17 PM EDT

Gyre Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
116.59105.76113.45102.297.34
Revenue Growth (YoY)
10.24%-6.78%10.91%1293.98%-82.48%
Cost of Revenue
5.423.884.644.797.38
Gross Profit
111.17101.87108.8197.5-0.04
Selling, General & Admin
85.9873.6275.8271.6118.96
Research & Development
13.712.0213.7816.6968.89
Other Operating Expenses
00.0786.44--
Total Operating Expenses
99.6985.71176.0488.2987.85
Operating Income
11.4916.16-67.239.2-87.89
Interest Income
1.751.551.041.58-
Other Non-Operating Income (Expense)
1.25.51-10.78-1.37-0.04
Total Non-Operating Income (Expense)
2.957.06-9.740.21-0.04
Pretax Income
14.4423.22-76.979.41-87.93
Provision for Income Taxes
4.565.328.525.1-
Net Income
5.0312.09-92.932.3-87.93
Minority Interest in Earnings
4.855.817.452.01-
Net Income to Common
5.0312.09-92.932.3-87.93
Net Income Growth
-58.40%----
Shares Outstanding (Basic)
8985666461
Shares Outstanding (Diluted)
103102667667
Shares Change (YoY)
0.87%55.39%-13.02%13.45%5117.44%
EPS (Basic)
0.060.14-1.410.040.26
EPS (Diluted)
0.020.05-1.410.030.24
EPS Growth
-60.00%---87.50%-
Free Cash Flow
-0.18-5.9617.385.69-84.59
Free Cash Flow Growth
--205.25%--
Free Cash Flow Per Share
-0.00-0.060.260.08-1.27
Gross Margin
95.35%96.33%95.91%95.31%-0.57%
Operating Margin
9.85%15.28%-59.26%9.00%-1197.79%
Profit Margin
8.47%16.92%-75.35%4.22%-1198.32%
FCF Margin
-0.15%-5.63%15.32%5.56%-1152.82%
EBITDA
13.9717.71-66.1610.29-87.6
EBITDA Margin
11.98%16.75%-58.31%10.06%-1193.84%
EBIT
11.4916.16-67.239.2-87.89
EBIT Margin
9.85%15.28%-59.26%9.00%-1197.79%
Effective Tax Rate
31.56%22.91%-11.06%54.16%0.00%
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q